by | Jan 16, 2026 | Publication
Improving detection of high-grade recurrences missed by WLC using a urinary biomarker Reviewed by Marek Babjuk Surveillance for non-muscle-invasive bladder cancer (NMIBC) relies on routine white-light cystoscopy (WLC) and urinary cytology as the diagnostic...
by | Sep 12, 2025 | Publication
The DaBlaCa-15 trial paves the way for urinary biomarker integration Reviewed by Joost Boormans Non-muscle-invasive bladder cancer (NMIBC) demands diligent and often lifelong surveillance, primarily through frequent cystoscopies. While crucial for detecting...
by | Jun 13, 2025 | Publication
Key perspectives from the EAU guidelines panel Reviewed by Paolo Gontero The current standard-of-care for NMIBC surveillance The 2025 EAU guidelines recommend cystoscopy as standard-of-care for the surveillance of all patients with non-muscle-invasive bladder...
by | Jul 5, 2024 | Publication
Reviewed by Marek Babjuk and Paolo Gontero The 2024 EAU guidelines mention a study concluding that FISH and Bladder EpiCheck® along with cytology could be helpful as an ancillary tool in the diagnosis of upper tract urothelial carcinoma (UTUC) [1]. The...
by | May 10, 2024 | Publication
Improvements in the initial diagnostic workup for bladder cancer Did you know that you can decrease your patient’s burden and discomfort during the initial workup for bladder cancer with the implementation of urinary biomarkers? According to the 2024 EAU...
by | Feb 2, 2024 | Publication
Reviewed by Mr. Hugh Mostafid (Royal Surrey County Hospital, Guildford, UK) UTUC: similarities and differences compared to bladder cancer While bladder tumours account for 90-95% of all urothelial carcinomas (UCa), only 5-10% of UCa cases involve the upper urinary...
